# Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors

> **NCT07625423** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Head & Neck Cancer
- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** EDS01 1.0×10^11 VP + Toripalimab
- **DRUG:** EDS01 5.0×10^11 VP + Toripalimab
- **DRUG:** EDS01 1.0×10^12 VP + Toripalimab

## Key facts

- **NCT ID:** NCT07625423
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625423, "Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07625423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*